Antibodies against merozoite surface protein (MSP)-119 are a major component of the invasion-inhibitory response in individuals immune to malaria

Journal of Experimental Medicine

Volumn 193, Issue 12, 2001, Pages 1403-1412

  O'Donnell, Rebecca A ^b   De Koning Ward, Tania F ^a,b   Burt, Rachel A ^b   Bockarie, Moses ^c,d   Reeder, John C ^c,d   Cowman, Alan F ^b   Crabb, Brendan S ^a,b,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^d PO Royal Melbourne Hospital ^*

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Human sera; Invasion; Malaria; Merozoite; Plasmodium

Indexed keywords

MEROZOITE SURFACE PROTEIN 1;

ANTIGEN EXPRESSION; ARTICLE; CELL INVASION; HUMAN; IMMUNE RESPONSE; MALARIA; MEROZOITE; NONHUMAN; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY SPECIFICITY; CELL DIVISION; CELL LINE; EPIDERMAL GROWTH FACTOR; HUMANS; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MICE; MOLECULAR SEQUENCE DATA; PARASITIC SENSITIVITY TESTS; PEPTIDE FRAGMENTS; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; TRANSFECTION;

EID: 0035908009     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.193.12.1403     Document Type: Article

References (42)

1. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection
2. Target antigens of purified human immunoglobulins which inhibit growth of Plasmodium falciparum in vitro
3. Differential effect of immunoglobulin on the in vitro growth of several isolates of Plasmodium falciparum
4. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes
5. Acquired immunity to asexual blood stages
6. Specific immunity acquired in man
7. The major merozoite surface protein as a malaria vaccine target
8. Pathways and strategies for developing a malaria blood-stage vaccine
9. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1
10. The crystal structure of C-terminal merozoite surface protein 1 at 1.8A resolution, a highly protective malaria vaccine candidate
11. 19 across distantly related Plasmodium species
12. A single fragment of a malaria merozoite surface protein remains on the parasite during red blood cell invasion and is the target of invasion-inhibiting antibodies
13. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1
14. Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1
15. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth
16. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro
17. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein
18. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species
19. Synchronization of Plasmodium falciparum erythrocytic stages in culture
20. Human malaria parasites in continuous culture
21. Characterization of promoters and stable transfection by homologous and nonhomologous recombination in Plasmodium falciparum
22. Stable transgene expression in Plasmodium falciparum
23. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil
24. A cDNA clone expressing a rhoptry protein of Plasmodium falciparum
25. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea
26. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1)
27. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase
28. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum
29. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum
30. Specificity of the protective antibody response to apical membrane antigen 1
31. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance
32. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1
33. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses
34. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: Associations with febrile illness, parasitemia, and anemia
35. Population structure and recent evolution of Plasmodium falciparum
36. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies
37. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys
38. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1
39. + T cells
40. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria
41. Immunization against malaria with a recombinant protein